Bifurcations have been, are and will be challenging. However, we have to admit we have gained experience and have more tools than pioneer interventionists and many of the early experts who have made history. This study assessed the ten-year trends in coronary bifurcation percutaneous coronary intervention (PCI) looking at patient and lesion characteristics, devices used,...
✔️ Day 2, SOLACI-CACI 2021 ✔️ Main Arena Auditorium 👨🏫 Program: 00:01 – TCT@SOLACI-CACI 2021 Session: “Structural Heart Interventions” 01:30:26 – CRT@SOLACI-CACI 2021 Session 02:51:13 – Oral presentation – Structural II 04:18:36 – Oral presentation – Coronary II 05:39:29 – IAGS@SOLACI-CACI 2021 Session 07:16:45 – Abbott Symposium – Using the MLD MAX Algorithm in OCT-Guided...
✔️ Watch again the Catheterization and Cardiovascular Interventions (CCI) Session in the SOLACI-CACI 2021 Congress. 👨🏫 Program: 01:44 – The Hybrid Algorithm in Complex Chronic Total Occlusion Percutaneous Coronary Intervention: Experience of a Latin-American Centre – Héctor Hugo Escutia Cuevas 21:12 – SYNTAX score II application compared to GRACE score for prediction of Heart Failure...
This large analysis found no benefit at a 1-year follow-up to angioplasty of non-culprit vessels in elderly patients admitted with ST-segment elevation myocardial infarction. The COMPLETE study was presented at the European Society of Cardiology 2019 Congress (and simultaneously published in NEJM) with evidence that seemed to leave no doubt regarding this issue. However, new...
The FLOWER-MI (presented simultaneously at ACC 2021 and NEJM) hit FFR hard. Its outcomes showed that STEMI patients presenting other non-culprit lesions did not benefit from FFR guided revascularization vs PCI. As it happens with most large studies with unexpected results in the general population, the sub-studies that follow select better samples and, as a...
Same day discharge following programed PCI with no complications has been a way for health centers to reduce costs that has resulted both safe and convenient for patients. With the arrival of the pandemic, reduced bed capacity, uninfected patient exposure and their potential contagion, and the always pressing need to reduce hospital costs have turned...
Patients initially receiving pharmacoinvasive strategy for ST elevation myocardial infarction (STEMI) also presenting multivessel disease consistently benefit from complete revascularization. This benefit is similar to that of primary PCI. The COMPLETE showed that staged non-culprit lesion percutaneous coronary intervention (PCI) reduced major cardiovascular events in STEMI patients with multivessel coronary artery disease. This benefit was...
PCI is far more successful at reducing ischemia when treating focal stable coronary artery disease (CAD). However, there were no differences in symptoms between both types of CAD. Physiological assessment with pressure wire pullback can be used to distinguish focal vs diffuse CAD, even though the relevance of this distinction has not been looked at...
Multivessel disease associated to ventricular function deterioration is challenging in terms of risk, when choosing a revascularization strategy. According to this recent analysis of the SCAAR registry published in the European Heart Journal, long term followup seems to justify taking a higher risk initially, higher risk being myocardial revascularization surgery (CABG). The study looked at...
This analysis corroborates the potential benefit of ticagrelor monotherapy following a short period of dual antiaggregation (DAPT) in patients with acute coronary syndrome (ACS). This benefit consists of a significant bleeding reduction (3.6% vs. 7.6%, P < 0.001), without compromising ischemic events (4.3% vs. 4.4%, P = 0.84). The latter, however, could be seen as...